Current Shortage of Rifapentine Tablets

Source: FDA · United States

Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

The FDA lists Rifapentine tablets as currently in shortage, but they are available from one manufacturer as of the latest update.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on May 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Rifapentine.

Current Shortage of Rifapentine Tablets

What's in Shortage

The drug in shortage is Rifapentine Tablet, Film Coated, with the generic name Rifapentine Tablet, Film Coated. The brand name is PRIFTIN. It is in tablet dosage form and falls under the therapeutic category of Anti-Infective. The current status is listed as current, with the shortage first posted on 03/25/2020 and last updated on 04/29/2026.

Which Manufacturers Are Affected

Sanofi-Aventis U.S. LLC is the manufacturer affected. Their availability status is available for the presentation Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24). Contact information for this manufacturer is 800-633-1610 Option 7.

Why There's a Shortage

No specific reason was given for the shortage.

What Patients Should Do

Patients experiencing issues with obtaining this medication should talk to their pharmacist or healthcare provider to check availability. They can also contact the manufacturer directly using the provided contact information. Please remember that patients should consult their healthcare provider for any advice related to their medication and not make changes without professional guidance.

Source

This information is sourced from the FDA Drug Shortage Database, with the shortage initially posted on 03/25/2020 and last updated on 04/29/2026.

Original source: FDA Official Notice ↗

All Drug Shortages →

Nationwide notices with similar length or severity timing 8

Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
The FDA lists Rifapentine tablets as currently in shortage, but they are available from one manufacturer as of the latest update.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "low" severity. No immediate action required, but stay aware.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.